Fig. 5From: The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritisTotal sIL-6R as PD marker for active drug exposure. Individual observed ALX-0061 (a) and total sIL-6R (b) concentration-time profiles are shown after a single intravenous administration of 100 mg/kg ALX-0061 in non-stimulated cynomolgus monkeys. PD: pharmacodynamic; sIL-6R: soluble IL-6RBack to article page